Nicotine pouches: an aid in smoking cessation, or a new public health hazard?

Tobacco harm reduction strategies aim to reduce the devastating health burden of smoking by providing lower-risk alternatives to those unable or unwilling to quit combustible cigarettes. Nicotine pouches have recently emerged as a novel, tobacco-free oral product category, evolving from the concept of Swedish snus but eliminating the tobacco leaf entirely. This narrative review assesses the current scientific evidence regarding the chemical composition, toxicological profile, nicotine delivery and smoking cessation efficacy, and potential public health impact of nicotine pouches. Chemical analyses and biomarker studies consistently demonstrate that these products occupy the lowest end of the toxicant risk continuum, with harmful constituents such as tobacco-specific nitrosamines being largely undetectable or present at negligible levels compared to snus and combustible cigarettes. Consequently, smokers who switch to nicotine pouches experience reductions in toxicant exposure comparable to complete smoking cessation. While specific long-term epidemiological data are currently unavailable, the extensive evidence on Swedish snus, which has not been linked to lung cancer or significant cardiovascular disease, provides a compelling "bridging" argument for the safety of these tobacco-free derivatives. Still, product-specific research and epidemiological surveillance is needed to confirm their long-term safety/risk profile, and healthcare professionals should consider recording the use of nicotine pouches in the medical history of patients. Furthermore, pharmacokinetic profiles suggest that modern pouches can deliver nicotine efficiently enough (although at a much slower rate than smoking) to alleviate cravings and displace combustible tobacco. There are some regulatory challenges that need to be explicitly addressed concerning labeling consistency, flavoring additives, and maximum nicotine limits. Current population data suggest they are unlikely to become a gateway to smoking, but continuous monitoring is warranted. In conclusion, nicotine pouches could represent a promising harm reduction tool with a risk profile likely adjacent to pharmaceutical nicotine replacement therapies, and could be considered by clinicians as substitutes for smoking in smokers unable or unwilling to quit with currently approved methods.